On January 23, 2026, hundreds of thousands of British users of the AI therapy app Ash opened it to find a farewell message instead of a chat window. Slingshot AI, the New York-based startup behind the app, had decided to pull Ash out of the United Kingdom entirely, citing a regulatory landscape it said made continued operation impossible. It was a rare and consequential retreat for one of the best-funded companies in the booming AI mental health space, and it exposed how unsettled the rules still are for tools that sit somewhere between a wellness app and a medical device.
From $93 Million Launch to Sudden Withdrawal
Slingshot AI had launched Ash with considerable fanfare in July 2025, backed by a Series A round that brought its total funding to $93 million, with investors including Andreessen Horowitz, Felicis, and Menlo Ventures. The company billed Ash as the first AI system built specifically for therapeutic conversation rather than adapted from a general-purpose chatbot, trained on clinical data and psychologist-designed prompts over an 18-month development period that included testing by more than 50,000 beta users. By July 2026 the app was free to download, with a paid subscription tier still in the works.
Then came the UK exit. In an email to users, Slingshot AI chief executive Daniel Reid Cahn wrote that there was no “clear regulatory pathway for wellbeing products like ours — and without that clarity, we can’t operate with confidence.” The company maintains that Ash is a wellbeing product, not a medical device, but UK regulators apparently view the line differently, putting Ash at risk of running afoul of the country’s medical device rules if it continued to operate as before.
A Gray Zone With No Clear Owner
The episode illustrates a problem that has dogged digital mental health tools for years: nobody has settled who regulates them or how. A chatbot that offers reflective questions and coping exercises can look, to a stressed or lonely user, indistinguishable from clinical treatment — yet it is typically marketed and priced like a consumer wellness subscription. UK authorities have signaled they intend to police that boundary more aggressively than their American counterparts, and Slingshot chose to leave the market rather than risk being classified as an unapproved medical device, according to reporting on the withdrawal. The company said it remains in discussions with the UK government to find a path back in.
The US Market Keeps Racing Ahead Regardless
Ash remains available and growing in the United States, where federal oversight of AI chatbots marketed for emotional support has lagged behind product releases. That gap has already prompted a handful of states to pass their own guardrails on AI therapy tools rather than wait for Washington, but no state has gone as far as pulling a consumer product outright the way UK regulators effectively forced Slingshot to do. The contrast is telling: the same app considered risky enough to warrant a full market exit in Britain continues to operate freely for millions of American users.
What Slingshot Says Ash Can and Can’t Do
Slingshot has been careful, at least publicly, to frame Ash’s limits. The company states plainly that Ash cannot diagnose conditions, prescribe treatment, or manage a mental health crisis — it is positioned as a support tool for stress, mood, and relationship reflection, not a replacement for a licensed clinician. Unlike general-purpose AI assistants that critics say are tuned to tell users what they want to hear, Slingshot says Ash runs on a special-purpose foundation model for psychology built specifically to avoid that trap. Whether that distinction persuades regulators elsewhere remains to be seen.
Why the UK Retreat Matters Beyond One App
Slingshot is not a fringe player experimenting on the margins; it is one of the most aggressively funded and rapidly scaled companies in AI mental health, which is exactly why its UK exit resonates across the industry. If a company with $93 million in venture backing and dedicated clinical infrastructure concluded it could not operate under British rules, smaller competitors with thinner compliance budgets are unlikely to try. Some industry watchers see the withdrawal as a preview of a wider reckoning coming to markets, including the US, once regulators catch up to the pace of product launches.
What Comes Next
For now, Ash’s UK users have been left to find alternatives, while Slingshot presses forward domestically and continues talks with British officials over a possible re-entry. The bigger unresolved question is whether the US Food and Drug Administration, or state legislatures acting in its place, will eventually draw the same hard line the UK did — treating AI chatbots that engage in therapeutic-style conversation as medical devices requiring formal clearance rather than consumer software governed by app-store terms of service. Until that happens, companies like Slingshot will keep expanding in whichever jurisdictions let them, testing the edges of a regulatory map that, as this episode shows, still has significant blank spots.
